Since the FH2 domain is essential for all known DIAPH1-mediated cellular effects, identification of drugs specifically blocking the interaction of FH2 with tubulin and actin, respectively, may be a promising new therapeutic approach for metastasizing colon cancers. This evidence concerns the gene DIAPH1 and malignant colon neoplasm.